Trial reportRadiology2025
MRI-based Radiomic Features for Risk Stratification of Ductal Carcinoma in Situ in a Multicenter Setting (ECOG-ACRIN E4112 Trial).
Trial report in Radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Next Frontier in Quantitative Co-Clinical Imaging to Advance Functional Precision Oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- A clinician-centric intelligent method towards reliable pancreatic cancer vascular invasion assessment: a retrospective, multi-centre study.The Lancet regional health. Western Pacific · 2026Article
- Multimodal radiomics incorporating intratumoral heterogeneity for prognostic assessment of metastatic outcomes in invasive breast cancer.Breast cancer research : BCR · 2026Article
- Imaging Ductal Carcinoma In Situ in the Era of De-Escalation: Role, Limits, and Clinical Implications for Risk-Adapted Management.Diagnostics (Basel, Switzerland) · 2026Review
- Nomogram for reducing unnecessary biopsies of breast lesions based on MRI and clinical features: a multi-center retrospective cohort study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
23 authors.
Funding
Abstract
Background Ductal carcinoma in situ (DCIS) is a nonlethal, preinvasive breast cancer for which breast MRI is best suited for accurate disease extent characterization. DCIS is often overtreated, necessitating robust models for improved risk stratification. Purpose To develop logistic regression models using clinical and MRI-based radiomic features of DCIS and to evaluate the performance of such models in predicting disease upstaging at surgery and DCIS score. Materials and Methods This study is a secondary analysis of dynamic contrast-enhanced (DCE) MRI data from the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, or ECOG-ACRIN, E4112 trial. Primary analysis focused on predicting disease upstaging (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.